Safety of enoxaparin in patients implanted with continuous flow left ventricular assist devices
Artificial Organs · 2025
DOI: 10.1111/aor.14908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Organs, 2025. Verfasst von Rachel C Klosko und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, New York, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Enoxaparin, Anticoagulants, Hemorrhage. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Background
The objective of this study is to determine the incidence of major bleeding events in patients implanted with continuous flow left ventricular assist devices (CF‐LVADs) bridged with enoxaparin (LMWH) compared to intravenous unfractionated heparin (IV UFH) for a subtherapeutic INR on warfarin.
Methods
A single‐center, retrospective, cohort study was conducted including patients with CF‐LVADs implanted between January 1, 2012 and July 1, 2020 who received at least one inpatient dose or outpatient prescription for LMWH or IV UFH at least 60 days after CF‐LVAD implantation. The primary endpoint was the incidence of major bleeding.
Results
In total, 176 orders were screened and 90 orders in 62 unique patients were included. Major bleeding and thromboembolic events occurred in 1 (2.5%) versus 4 (10.0%) orders ( p = 0.36) and 3 (7.5%) versus 1 (2.5%) orders ( p = 0.62) in the LMWH and IV UFH groups, respectively. One patient had a fatal thromboembolic event in each group. More patients receiving IV UFH had minor bleeding events (10 [25.0%] vs. 3 [7.5%]; p = 0.03).
Conclusions
There was no difference between bleeding and thromboembolic events in patients implanted with CF‐LVADs prescribed LMWH or IV UFH for bridging of subtherapeutic INRs. Larger prospective randomized data are needed to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, New York, USA.
- Division of Cardiac Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
- Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
- Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA.
- US Clinical Development, Medical and Regulatory Affairs, Novonordisk, Rochester, Minnesota, USA.
ORCID-Profile: Rachel C Klosko
Förderung
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Klosko, R. C., Whitson, B., Lampert, B., McLaughlin, E., & Orzel, L. (2025). Safety of enoxaparin in patients implanted with continuous flow left ventricular assist devices. Artificial Organs. https://doi.org/10.1111/aor.14908
Vancouver
Klosko RC, Whitson B, Lampert B, McLaughlin E, Orzel L. Safety of enoxaparin in patients implanted with continuous flow left ventricular assist devices. Artificial Organs. 2025. doi:10.1111/aor.14908
BibTeX
@article{Klosko2025,
author = {Klosko, Rachel C and Whitson, Bryan and Lampert, Brent and McLaughlin, Eric and Orzel, Libby},
title = {Safety of enoxaparin in patients implanted with continuous flow left ventricular assist devices},
journal = {Artificial Organs},
year = {2025},
doi = {10.1111/aor.14908}
}
EUVIMED